254 related articles for article (PubMed ID: 32676358)
1. Clinical significance of histologic subtyping of malignant pleural mesothelioma.
Brcic L; Kern I
Transl Lung Cancer Res; 2020 Jun; 9(3):924-933. PubMed ID: 32676358
[TBL] [Abstract][Full Text] [Related]
2. Pathohistological diagnosis and differential diagnosis.
Tischoff I; Neid M; Neumann V; Tannapfel A
Recent Results Cancer Res; 2011; 189():57-78. PubMed ID: 21479896
[TBL] [Abstract][Full Text] [Related]
3. The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification.
Galateau-Salle F; Churg A; Roggli V; Travis WD;
J Thorac Oncol; 2016 Feb; 11(2):142-54. PubMed ID: 26811225
[TBL] [Abstract][Full Text] [Related]
4. New Insights in Pleural Mesothelioma Classification Update: Diagnostic Traps and Prognostic Implications.
Mastromarino MG; Lenzini A; Aprile V; Alì G; Bacchin D; Korasidis S; Ambrogi MC; Lucchi M
Diagnostics (Basel); 2022 Nov; 12(12):. PubMed ID: 36552912
[TBL] [Abstract][Full Text] [Related]
5. Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma.
Kadota K; Suzuki K; Sima CS; Rusch VW; Adusumilli PS; Travis WD
J Thorac Oncol; 2011 May; 6(5):896-904. PubMed ID: 21358344
[TBL] [Abstract][Full Text] [Related]
6. The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification.
Sauter JL; Dacic S; Galateau-Salle F; Attanoos RL; Butnor KJ; Churg A; Husain AN; Kadota K; Khoor A; Nicholson AG; Roggli V; Schmitt F; Tsao MS; Travis WD
J Thorac Oncol; 2022 May; 17(5):608-622. PubMed ID: 35026477
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis of Mesothelioma.
Fels Elliott DR; Jones KD
Surg Pathol Clin; 2020 Mar; 13(1):73-89. PubMed ID: 32005436
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic surgery for nonepithelioid malignant pleural mesothelioma: is it really worthwhile?
Balduyck B; Trousse D; Nakas A; Martin-Ucar AE; Edwards J; Waller DA
Ann Thorac Surg; 2010 Mar; 89(3):907-11. PubMed ID: 20172152
[TBL] [Abstract][Full Text] [Related]
9. Malignant peritoneal mesothelioma: correlation between CT imaging features and histologic subtypes.
Atre ID; Watane GV; Harisinghani MG
Abdom Radiol (NY); 2021 Nov; 46(11):5105-5113. PubMed ID: 34342707
[TBL] [Abstract][Full Text] [Related]
10. Well-differentiated papillary mesothelioma of the pleura: a series of 24 cases.
Galateau-Sallé F; Vignaud JM; Burke L; Gibbs A; Brambilla E; Attanoos R; Goldberg M; Launoy G;
Am J Surg Pathol; 2004 Apr; 28(4):534-40. PubMed ID: 15087673
[TBL] [Abstract][Full Text] [Related]
11. Unusual intraparenchymal growth patterns of malignant pleural mesothelioma.
Nind NR; Attanoos RL; Gibbs AR
Histopathology; 2003 Feb; 42(2):150-5. PubMed ID: 12558747
[TBL] [Abstract][Full Text] [Related]
12. Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA.
Henderson DW; Reid G; Kao SC; van Zandwijk N; Klebe S
J Clin Pathol; 2013 Oct; 66(10):854-61. PubMed ID: 23833051
[TBL] [Abstract][Full Text] [Related]
13. Primary thymic epithelial tumours of the pleura mimicking malignant mesothelioma.
Attanoos RL; Galateau-Salle F; Gibbs AR; Muller S; Ghandour F; Dojcinov SD
Histopathology; 2002 Jul; 41(1):42-9. PubMed ID: 12121236
[TBL] [Abstract][Full Text] [Related]
14. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
15. Comparison of conventional and novel PET tracers for imaging mesothelioma in nude mice with subcutaneous and intrapleural xenografts.
Tsuji AB; Sogawa C; Sugyo A; Sudo H; Toyohara J; Koizumi M; Abe M; Hino O; Harada YN; Furukawa T; Suzuki K; Saga T
Nucl Med Biol; 2009 May; 36(4):379-88. PubMed ID: 19423005
[TBL] [Abstract][Full Text] [Related]
16. Diffusion-weighted MRI of malignant pleural mesothelioma: preliminary assessment of apparent diffusion coefficient in histologic subtypes.
Gill RR; Umeoka S; Mamata H; Tilleman TR; Stanwell P; Woodhams R; Padera RF; Sugarbaker DJ; Hatabu H
AJR Am J Roentgenol; 2010 Aug; 195(2):W125-30. PubMed ID: 20651171
[TBL] [Abstract][Full Text] [Related]
17. Gene Expression Analysis of Biphasic Pleural Mesothelioma: New Potential Diagnostic and Prognostic Markers.
Bruno R; Poma AM; Alì G; Distefano C; Proietti A; Chella A; Lucchi M; Melfi F; Franco R; Fontanini G
Diagnostics (Basel); 2022 Mar; 12(3):. PubMed ID: 35328227
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma.
Wu D; Hiroshima K; Yusa T; Ozaki D; Koh E; Sekine Y; Matsumoto S; Nabeshima K; Sato A; Tsujimura T; Yamakawa H; Tada Y; Shimada H; Tagawa M
Ann Diagn Pathol; 2017 Feb; 26():31-37. PubMed ID: 28038708
[TBL] [Abstract][Full Text] [Related]
19. A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters.
Nowak AK; Francis RJ; Phillips MJ; Millward MJ; van der Schaaf AA; Boucek J; Musk AW; McCoy MJ; Segal A; Robins P; Byrne MJ
Clin Cancer Res; 2010 Apr; 16(8):2409-17. PubMed ID: 20371686
[TBL] [Abstract][Full Text] [Related]
20. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.
Cury PM; Butcher DN; Corrin B; Nicholson AG
J Pathol; 1999 Oct; 189(2):251-7. PubMed ID: 10547583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]